Teva has responded to a supplementary statement of objections issued by the European Commission over a settlement deal with Cephalon on modafinil by insisting that it will robustly rebut the criticism.
Teva Will Rebut Latest EU Competition Criticism
Supplementary Statement Of Objections Issued By Commission Over Modafinil
In the wake of the European Commission issuing Teva with a supplementary statement of objections over a historical “pay for delay” patent settlement agreement on modafinil with Cephalon, the Israeli firm has insisted on its right to reply.
